Clinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Network

This phase 4 study investigated the influence of pregnancy on the pharmacokinetics of elvitegravir/cobicistat in 14 women with human immunodeficiency virus type 1. The results support the recommendation against elvitegravir/cobicistat use during pregnancy, as the elvitegravir concentration at the en...

Descripción completa

Detalles Bibliográficos
Autores principales: Bukkems, Vera, Necsoi, Coca, Tenorio, Carmen Hidalgo, Garcia, Coral, Rockstroh, Jürgen, Schwarze-Zander, Caroline, Lambert, John S, Burger, David, Konopnicki, Deborah, Colbers, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Online Only Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744974/
https://www.ncbi.nlm.nih.gov/pubmed/32330231
http://dx.doi.org/10.1093/cid/ciaa488
Descripción
Sumario:This phase 4 study investigated the influence of pregnancy on the pharmacokinetics of elvitegravir/cobicistat in 14 women with human immunodeficiency virus type 1. The results support the recommendation against elvitegravir/cobicistat use during pregnancy, as the elvitegravir concentration at the end of the dosing interval (C(trough)) was reduced by 77%, with 85% of pregnant women having a C(trough) below the effective concentration (EC(90)). Clinical Trials Registration. NCT00825929.

Ejemplares similares